The interaction properties of costimulatory molecules revisited.
By A. Collins, D. Brodie, R. Gilbert, Andrea Iaboni, R. Manso-Sancho, B. Walse, David I. Stuart, P. A. van der Merwe, S. Davis. Immunity, 2002
699 citations recorded by the source corpus.
Subfields: Computational Theory and Mathematics, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/8bd9b307b2ed28f15243f9a9dc575f445021df4b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- Andre Franke
- Alejandro A. Schäffer
- Craig B. Thompson
- Peter S. Linsley
- Rolf Backofen
- Ralph J. Deberardinis
- M. V. Vander Heiden
- Guido Kroemer
Citations in the corpus
- Autosomal-dominant immune dysregulation syndrome in humans with CTLA4 mutations (2014, positive): “The discovery of heterozygous loss-of-function mutations in CTLA4 suggests that the CD28 and CTLA-4 pathway may be targeted in selected subsets of patients with inflammatory bowel disease, enteropathy and wasting disease, granulomatous lung disease, and autoimmune cytopenias.”
- Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. (2007, neutral): “34 μM, similar to published values (Collins et al., 2002).”
- Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production 1 (2003, neutral): “small monomeric affinity differences (30).”
- Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self (2005, background): “Furthermore, the expression of CD80 or CD86 may differentially activate or deactivate T reg cells; for example, CD80 has much higher affinity for CTLA-4 than does CD86; similarly, CD86 has a higher affinity for CD28 than does CD80 (refs”
- The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses (2011, methodology): “constant (K d ), as reported by Collins et al.(30).”
- CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms (2004, background): “CTLA-4 shares the B7 ligand with CD28 but binds with a higher avidity (20); thus, ligand sequestration may be significant in vivo (9).”